These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 23496764)

  • 1. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
    Huang L; Counter CM
    PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute Quantification of Endogenous Ras Isoform Abundance.
    Mageean CJ; Griffiths JR; Smith DL; Clague MJ; Prior IA
    PLoS One; 2015; 10(11):e0142674. PubMed ID: 26560143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
    Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
    Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
    To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
    Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of liver oncogenic potential among human RAS isoforms.
    Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
    Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.
    Nussinov R; Zhang M; Tsai CJ; Jang H
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2304-2314. PubMed ID: 29097261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
    Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
    Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
    Sheffels E; Sealover NE; Theard PL; Kortum RL
    Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential oncogenic potential of activated RAS isoforms in melanocytes.
    Whitwam T; Vanbrocklin MW; Russo ME; Haak PT; Bilgili D; Resau JH; Koo HM; Holmen SL
    Oncogene; 2007 Jul; 26(31):4563-70. PubMed ID: 17297468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of wild type RAS isoforms in cancer.
    Zhou B; Der CJ; Cox AD
    Semin Cell Dev Biol; 2016 Oct; 58():60-9. PubMed ID: 27422332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model for RAS mutation patterns in cancers: finding the sweet spot.
    Li S; Balmain A; Counter CM
    Nat Rev Cancer; 2018 Dec; 18(12):767-777. PubMed ID: 30420765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma.
    Vagaja NN; Parry J; McCallum D; Thomas MA; Bentel JM
    J Clin Pathol; 2015 Aug; 68(8):657-60. PubMed ID: 25926041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment.
    Czajkowski R
    Int J Dermatol; 2011 Feb; 50(2):180-3. PubMed ID: 21244382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
    Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
    J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.
    Guruvaiah P; Gupta R
    J Transl Med; 2024 Jul; 22(1):642. PubMed ID: 38982514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.